CD19 and B-cell non-Hodgkin lymphoma: At the cellular level, SLS dose-dependently promoted the killing effect of unmodified T cells and anti-CD19 CAR-T cells on Raji cell lines, while at the same time reducing T-cell and CAR-T cell exhaustion to a certain extent, promoting the proliferation of anti-CD19 CAR-T cells, decreasing the levels of IL-6, IL-10, and TNF-α, and increasing the levels of granzyme B. SLS in in vivo studies effectively increased the anti-B-cell lymphoma function of anti-CD19 CART cells, prolonged the survival of mice, and decreased the levels of IL-6, GM-CSF, and IL-17.